The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CR3 or N Y is CR3 or N L is selected from —NR2C(O)—, —C(O)NR2— and —NR2CRaRb— Ra and Rb are independently hydrogen, halogen or substituted or unsubstituted alkyl ring E is selected from the Formula (i) to (vii).
